Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.

Conditions

Gram-negative Bacterial Infection

Interventions

DRUG: Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3
DRUG: Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3

Sponsor

Pfizer

Collaborators

[object Object]